Dusquetide
Also known as: Dusquetide, dusquetide acetate, EP‑647, IMX942, SGX942
Source Dusquetide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dusquetide (EP‑647) is a synthetic host‑defense‑peptide‑derived compound under clinical investigation for prevention and treatment of oral mucositis and for inflammatory bowel disease.
Mechanism of Action
Modulates innate immune signaling via p38 MAPK activation, enhances antimicrobial peptide expression and reduces pro‑inflammatory cytokine release.
Routes of Administration
Goals & Uses
- Acceleration of mucosal healingTissue RepairModerate
- Preservation of anti-tumor and antimicrobial immunityImmune ModulationLow
- Oral mucositis preventionOncology Supportive CareModerate
- Improvement in quality of life during cancer treatmentSupportive Oncology CareModerate
- Inflammatory bowel diseaseGastroenterologyLow
- Reduction of oral mucositis severityAnti Inflammatory / Mucosal ProtectionModerate
Contraindications
- Known hypersensitivity to Dusquetide or excipientsAllergyHigh
- Known hypersensitivity to dusquetide or any component of the formulationAllergy/hypersensitivityHigh
Adverse Effects
- Injection site reactionsLocalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- DiarrheaGastrointestinalUncommonLoose or frequent stools
Drug Interactions
- Concurrent immunosuppressantsModerate
- Cytotoxic chemotherapy agents (e.g., cisplatin, carboplatin)Low
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
Population Constraints
- Severe renal or hepatic impairmentOrgan FunctionRelative
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalNo marketing authorization; clinical studies in progress.
- United StatesInvestigationalIND holder; Phase III trials ongoing.
Investigational New Drug (IND) status in the US; not approved in any jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dusquetide?
Dusquetide (EP‑647) is a synthetic host‑defense‑peptide‑derived compound under clinical investigation for prevention and treatment of oral mucositis and for inflammatory bowel disease.
What is Dusquetide used for?
Dusquetide is educationally associated with: Acceleration of mucosal healing, Preservation of anti-tumor and antimicrobial immunity, Oral mucositis prevention, Improvement in quality of life during cancer treatment, Inflammatory bowel disease, Reduction of oral mucositis severity. Educational only — not medical advice.
How is Dusquetide administered?
Recorded routes of administration: Intravenous, Oral, Subcutaneous.
What are the potential side effects of Dusquetide?
Reported adverse effects include: Injection site reactions, Headache, Nausea, Fatigue, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dusquetide?
Recorded contraindications: Known hypersensitivity to Dusquetide or excipients, Known hypersensitivity to dusquetide or any component of the formulation. Consult a qualified clinician before use.